Conversations about mushrooms and the brain often split into two extremes: aggressive marketing for "brain-boosting capsules" or blanket dismissal. Both attitudes miss what fungi actually offer. Over the past fifteen years, a coherent line of human research has emerged — involving not only extracts of lion's mane, but everyday culinary mushrooms from the grocery store.
What everyday diet showed: the DaHA cohort (n=663)
In 2019, Barry Halliwell and Lei Feng's team in Singapore published an analysis of the Diet and Healthy Aging (DaHA) cohort — 663 community-dwelling adults aged 60 and older (study card, Journal of Alzheimer's Disease, PMID 30775990). They tracked intake of everyday mushrooms: golden, oyster, shiitake and white button mushrooms.
Participants eating more than 2 portions of mushrooms per week (~300 g+ total) had roughly half the odds of mild cognitive impairment (MCI) compared with those eating less than one portion: OR = 0.43 (95% CI 0.23–0.78; p = 0.006). The association held after adjusting for age, education, hypertension, diabetes, heart disease, physical and social activity.
The honest caveat: this was a cross-sectional study measuring diet and cognitive status at a single point in time, so it cannot prove causation on its own.
Why blood ergothioneine predicts decline (n=470)
The same research group followed up with a prospective cohort of 470 older memory-clinic patients in Singapore tracked for up to 5 years with brain MRI (study card, Antioxidants, 2022, PMID 36139790).
- Lower baseline plasma ergothioneine predicted faster decline across memory, attention, executive function and visuomotor speed — specifically in non-demented participants at the pre-dementia stage.
- Mediation analysis showed that much of this link was explained by cerebrovascular disease burden and brain atrophy. That nuance matters: mushroom-derived ergothioneine acts both as a candidate cytoprotectant and as a sensitive marker of vascular and metabolic brain health.
A real-food trial: tamogitake and the gut–brain axis (n=170)
In 2025, a Japanese trial in 170 older adults (aged 60–79) tested 8 weeks of dried golden oyster mushroom (tamogitake) — one of the richest natural sources of ergothioneine — alongside 16S microbiota sequencing and Cognitrax testing (study card, Frontiers in Nutrition, PMID 40761356).
Participants whose cognitive scores improved also showed increases in beneficial gut taxa (Faecalibacterium, Blautia and others), yet the authors were candid: there was no universal effect for everyone; response depended on matching the mushroom substrate to an individual's baseline microbiota.
A clinical supplement example: lion's mane in MCI (Mori 2009, n=30)
Lion's mane stands apart because of its hericenones and erinacines, which stimulate nerve growth factor (NGF) synthesis in preclinical models. In a classic 16-week double-blind RCT by Mori et al. (study card, Phytotherapy Research, 2009, PMID 18844328), 30 adults aged 50–80 with diagnosed MCI received 3 g/day of dry fruiting-body powder or placebo.
At weeks 8, 12 and 16, cognitive scores (HDS-R) were significantly higher in the lion's mane group than placebo, but declined again within 4 weeks after stopping. Because the sample was small (n = 30) and the trial was run by a manufacturer's lab, larger independent trials are still needed.
A balanced takeaway
- Start in the kitchen, not the supplement aisle. Regular culinary mushrooms (2+ servings a week in observational data) supply ergothioneine, which the human body actively retains in tissues including the brain.
- Do not expect an instant "nootropic surge". Even in positive lion's mane trials, measurable changes took 8–16 weeks and faded after discontinuation.
- Brain health is systemic. Mushrooms complement sleep, exercise, vascular care and an overall balanced diet — they do not replace them.
Limits of knowledge
- The link between 2+ weekly mushroom servings and lower MCI odds comes from observational data and awaits long-term randomized dietary trials.
- Pilot RCTs of lion's mane and ergothioneine in MCI remain small and require independent multicenter replication.